Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-06-10

Clinical Trial Update: Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men [Phase 3]

View source ↗

Summary

Phase 3 trial update on ambulatory blood pressure monitoring in men with hypogonadism treated with oral testosterone undecanoate (LPCN 1021).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oral testosterone undecanoate (testosterone undecanoate)

Snippet

Sponsor: Lipocine Inc. | Conditions: Hypogonadism, Male | Phase 3 | Status: COMPLETED | Results posted: 2021-06-10